For example, the small molecule HER2 inhibitor tucatinib was investigated in combination with capecitabine or ado‐trastuzumab emtansine in a phase Ib study with enrollment restricted to HER2+ breast cancer designed to evaluate the safety and tolerability of the combination and assess preliminary efficacy. Here, ERBB2 is linked to breast carcinoma.